Safety and efficacy of galcanezumab in chronic and episodic migraine patients: a systematic review and meta-analysis of randomized controlled trials

• Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery Vol. 60; no. 1; pp. 60 - 15
• Main Authors: Zaazouee, Mohamed Sayed, Ebrahim, Rokaya Y., Al-araj, Ghaida’a, Zaki, Ibram, Saad, Ahmed, Farhat, Abdullah Mohamed, Ali, Mustafa Hussein, Elshennawy, Mohamed, Fawy, Omar Khaled Fahmy, Ahmed, Hadi F., Alahmad, Ziad, Nada, Eman Ayman, Abo-Hamra, Reem I., Elsnhory, Ahmed Bostamy, Eleyan, Mohammed, AbuEl-Enien, Hazem, Elromely, Rasha Abdo, AbdelQadir, Yossef Hassan, Shah, Jaffer, Elshanbary, Alaa Ahmed
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 13.05.2024; Springer Nature B.V; SpringerOpen
• Subjects: Clinical trials; Galcanezumab; Headache; LY2951742; Medicine; Medicine & Public Health; Meta-analysis; Migraine; Neurology; Neurosurgery; Psychiatry; Response rates; Review; Systematic review; Headache; LY2951742; Galcanezumab; Migraine; Meta-analysis
• ISSN: 1110-1083; 1687-8329
• DOI: 10.1186/s41983-024-00834-8

Background The humanized monoclonal antibody galcanezumab is an anti-calcitonin-gene-related-peptide (CGRP) and frequently used for migraine prevention. However, the literature revealed limited data with conflicting results. This study aims to assess the safety and efficacy of galcanezumab in treating patients with episodic or chronic migraine. Methods We searched for randomized controlled trials till September 2022 from six databases (Cochrane library, Embase, PubMed, Web of Science, Scopus, and Clinicaltrials.gov registry). Our primary outcomes were the change in the number of monthly migraine headache days (MHDs) and adverse events. We extracted the data and analyzed it by RevMan (5.4) software. Results Eight studies with 4964 patients were included. Galcanezumab (≥ 120 mg) significantly reduced the MHDs for six months in migraine patients compared to placebo. The monthly risk ratio (RR) ranged from − 2.33 to − 1.62 for episodic migraine and − 2.86 to − 2.44 for chronic migraine. The response rate of ≥ 50%, ≥ 75% and 100% were higher with galcanezumab groups. The rate ranged from 1.72 to 4.19 for episodic migraine and 1.84 to 2.47 for chronic migraine. It is generally safe except for injection site safety outcomes (erythema, reaction, pruritis, and swelling), the results were significantly higher with galcanezumab groups. It appears dose independent except for injection site reaction, which showed higher with galcanezumab 120 mg only. Furthermore, any adverse events, serious adverse events (SAE) and that led to discontinuation were higher with galcanezumab 240 mg. Conclusion Galcanezumab is effective in patients with episodic or chronic migraine after one to six months use. It reduced MHDs and had an effective response rate. Moreover, it is generally safe except for injection site adverse events, and SAE, especially with galcanezumab 240mg.